Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Royalty Pharma Plc Cl A (RPRX)

Royalty Pharma Plc Cl A (RPRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 26,748,858
  • Shares Outstanding, K 576,857
  • Annual Sales, $ 2,378 M
  • Annual Income, $ 770,950 K
  • EBIT $ 1,560 M
  • EBITDA $ 1,592 M
  • 60-Month Beta 0.40
  • Price/Sales 11.24
  • Price/Cash Flow 9.70
  • Price/Book 2.75

Options Overview Details

View History
  • Implied Volatility 47.47% (+13.49%)
  • Historical Volatility 20.92%
  • IV Percentile 71%
  • IV Rank 50.16%
  • IV High 75.80% on 01/14/26
  • IV Low 18.96% on 05/21/25
  • Expected Move (DTE 17) 2.93 (6.19%)
  • Put/Call Vol Ratio 0.12
  • Today's Volume 282
  • Volume Avg (30-Day) 137
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 14,604
  • Open Int (30-Day) 14,248
  • Expected Range 44.47 to 50.33

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.17
  • Number of Estimates 2
  • High Estimate 1.18
  • Low Estimate 1.17
  • Prior Year 1.06
  • Growth Rate Est. (year over year) +10.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
44.73 +6.17%
on 03/20/26
47.86 -0.77%
on 03/04/26
+1.28 (+2.77%)
since 02/27/26
3-Month
38.29 +24.03%
on 01/02/26
47.86 -0.77%
on 03/04/26
+8.26 (+21.09%)
since 12/26/25
52-Week
29.66 +60.11%
on 04/07/25
47.86 -0.77%
on 03/04/26
+16.11 (+51.39%)
since 03/28/25

Most Recent Stories

More News
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm

1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm

RPRX : 47.54 (+2.52%)
CHRD : 144.19 (-1.40%)
DOCU : 47.79 (+1.12%)
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases

NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million...

RPRX : 47.54 (+2.52%)
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?

Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?

RPRX : 47.54 (+2.52%)
Royalty Pharma Appoints Lucas Glass as Head of Artificial Intelligence

NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead...

RPRX : 47.54 (+2.52%)
Royalty Pharma Announces Expansion of Leadership Team

NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President, Partnering...

RPRX : 47.54 (+2.52%)
Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharma's Global Platform

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026. Ken will be...

RPRX : 47.54 (+2.52%)
Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain...

RPRX : 47.54 (+2.52%)
ZYME : 24.94 (+3.02%)
Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

Zymeworks to receive $250 million under a royalty-backed note financing from Royalty Pharma with repayments due from 30% of worldwide tiered royalties on Ziihera until fully repaid Zymeworks to retain...

RPRX : 47.54 (+2.52%)
ZYME : 24.94 (+3.02%)
Royalty Pharma to Present at TD Cowen’s 46th Annual Health Care Conference

NEW YORK, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 46 th Annual Health Care Conference on March...

RPRX : 47.54 (+2.52%)
3 Healthcare Stocks Walking a Fine Line

3 Healthcare Stocks Walking a Fine Line

RPRX : 47.54 (+2.52%)
MTD : 1,270.20 (+1.78%)
RVTY : 87.73 (+3.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Royalty Pharma plc is a funder of biopharmaceutical industry. The compnay's portfolio includes royalties on commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta and Vertex's Kalydeco, Symdeko...

See More

Key Turning Points

3rd Resistance Point 47.35
2nd Resistance Point 47.04
1st Resistance Point 46.71
Last Price 47.54
1st Support Level 46.07
2nd Support Level 45.76
3rd Support Level 45.43

See More

52-Week High 47.86
Last Price 47.54
Fibonacci 61.8% 40.91
Fibonacci 50% 38.76
Fibonacci 38.2% 36.61
52-Week Low 29.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.